Complement dysregulation is known to contribute to a wide range of disease processes. [1] [2] [3] [4] [5] Recent studies strongly suggest that complement hyperactivation plays an essential role in the development of various clinical phenotypes of thrombotic microangiopathies (TMAs). 6, 7 Atypical hemolytic uremic syndrome (aHUS) is a type of TMA caused by excessive complement activation secondary to either an inherited defect and/or acquired antibody impairing the regulatory function of the complement system. The genetic abnormalities in patients with aHUS may involve regulators of complement-alternative pathways such as factor H, factor I, or complement activation factors. 8 A specific complement inhibitor, eculizumab, has been approved by the US Food and Drug Administration for the treatment of aHUS. 4, 9, 10 New studies also have shown that complement activation biomarkers are elevated in patients with another type of TMA, thrombotic thrombocytopenic purpura (TTP). 11, 12 The severity of increases in complement biomarker levels appears related to worse clinical outcomes in TTP. 13 Involvement of the complement system in TTP's disease course is also supported by a report that a patient with TTP refractory to plasma exchange therapy achieved long-term remission after being treated with a complement inhibitor (anti-C5). 14 Furthermore, in patients with hematopoietic stem cell transplant (HSCT)-associated TMA, a study has shown a high prevalence of factor H-related gene deletion and factor H autoantibodies, suggesting that dysregulation of the complement-alternative pathway may contribute to the pathogenesis of post-HSCT TMA. 15 Taken together, these studies support the role of complement dysfunction in the development of TMA and provide a basis for using complement biomarkers clinically to evaluate patients with TMA.
Assays for C3, C4, and CH50 have been used routinely for evaluation of complement pathways in clinical laboratories. However, these tests are generally not sensitive to the alterations in the complement system that occur in many diseases. For instance, in patients with aHUS and evidence of a genetic mutation, less than 50% show abnormal results when tested for C3, C4, and CH50 levels, [16] [17] [18] [19] [20] and consequently, these complement levels are not routinely used to diagnose, monitor, and manage patients with aHUS. We hypothesize that the downstream proteolytic fragments of the complement system are more sensitive to subtle dysregulation in the complement pathway. These candidate downstream biomarkers include C3a, C4d, terminal pathway activation product C5b-9 and C5a, and a product of the amplification loop, complement factor Bb. We and others have recently evaluated the performance of these downstream complement biomarkers and provided supporting evidence for their application in clinical evaluation of various types of TMAs. 11, 13, 21 The analysis of complement biomarker levels in research studies and in the clinic is complex and subject to significant inaccuracies due in part to variation in sample collection and handling. 20, [22] [23] [24] Despite the considerable concern for potential false-positive results in the tests for complement biomarkers, there has been a lack of studies fully investigating preanalytical effects on complement biomarker assays. In this study, we performed a detailed evaluation of how specimen sampling, processing, and storage conditions affect the results of biomarker assays for complement activation products C3a, C4d, C5a, C5b-9, and factor Bb. The objective of the study is to provide guidelines for clinical and research laboratories with regard to the handling of specimens for complement assays and ultimately to ensure that more accurate and reliable complement assays are being used in both clinical and research evaluation of patients with abnormal complement functions.
Materials and Methods

Standard Protocol for Sample Processing
Blood from three study donors was collected in three types of tubes: anticoagulated with EDTA, 3.6% sodium citrate, and without anticoagulant for preparation of serum. Upon blood draw, the serum collection tubes were inverted five times, allowed to stand at room temperature (RT) for 30 minutes, and then spun at 1,300g for 10 minutes. The supernatant was collected, aliquoted, and frozen in a -80°C freezer. For both EDTA and citrate anticoagulated specimens, samples were spun at 1,000g for 10 minutes to obtain an initial plasma preparation. After transferring the initial plasma to a new tube, the sample underwent a second spin at 12,000g for 2 minutes to obtain the final platelet-poor plasma for study. All samples were processed as quickly as possible after blood collection from study donors. All spins were carried out in a refrigerated (4°C) centrifuge. Upon completion of processing, the samples were aliquoted and immediately frozen in a -80°C freezer.
Effect of Blood Handling Prior to Sample Processing
To evaluate the effect different handling conditions have on test results, we subjected the citrate and EDTA whole-blood samples to various storage conditions before centrifugation to obtain the plasma samples. After the blood draws, one set of blood samples was stored at RT for 1, 2, 4, and 8 hours, respectively, before being processed for plasma. A second set of samples was stored in a 4°C refrigerator for 3, 24, and 48 hours prior to being processed.
Effect of Sample Thawing Conditions
Serum, citrate, and EDTA plasma frozen (-80°C) samples were thawed under three different conditions: (1) sample aliquots (200 mL for each sample) were placed on the top of an ice bucket for thawing. On average, it took around 30 minutes for the samples to be thawed completely under this condition. (2) Sample tubes were placed in a RT water bath for 5, 10, 30, and 60 minutes. (3) Sample tubes were placed in a 37°C water bath for 5, 10, 30, and 60 minutes. Upon completion of each thawing condition, the sample tube was immediately placed on ice and then stored in a -80°C freezer until complement biomarker assays were performed for comparison.
Effect of Different Freeze/Thaw Cycles
Multiple aliquots were made from each study sample and then frozen (-80°C) immediately after the initial processing. For this study, different sets of study samples were subjected to a different number of freeze/thaw cycles (one to four times). For the samples undergoing multiple freeze/ thaw process, the initially frozen samples were thawed in a RT water bath with frequent monitoring. Immediately upon thawing, the samples were put on ice and transferred into a -80°C freezer for the next freezing cycle.
Effect of Long-Term Storage of Citrate Plasma Samples From Patients With TTP
To determine the stability of complement biomarkers during long-term storage, we compared the performance of biomarkers in samples obtained over time from patients with TTP and stored over a 6-year period at -80°C. In our TTP cohort, there were a total of 88 episodes of TTP from 51 patients with TTP between 2006 and 2012. At the time of each TTP episode, the pretreatment sample was collected in citrated blood and processed freshly according to the DOI: 10.1309/AJCPXPD7ZQXNTIAL
© American Society for Clinical Pathology standard protocol, and then 20 aliquots from each sample were banked immediately at -80°C. For this study, one aliquot from each of these 88 samples was thawed in 2012, and the levels of complement biomarkers were measured for comparison. All samples banked from 2006 to 2012 were thawed only once for study.
Complement Biomarker Assays
Complement biomarkers C4d, factor Bb, C3a, C5a, and C5b-9 were measured by using commercial enzyme-linked immunosorbent assay kits. The assay kits for C4d (A008), factor Bb (A027), C3a (A031), and C5b-9 (A020) were from Quidel (Santa Clara, CA). The assay kit for C5a (557965) was from BD Biosciences (Franklin Lakes, NJ). The analytical performance of these assays was examined prior to the start of this study. Initial analysis of the C5b-9 assay resulted in unsatisfactory test reproducibility (interassay coefficient of variation [CV] >50%) using the manufacturer's protocol. Subsequently, we evaluated various assay conditions and their effects on the test performances of all complement assays. In the end, we modified the assay procedures for all assays by including 10 mmol/L EDTA and 1% bovine serum albumin in both assay buffer and sample diluent. By using the modified assay protocols, all assays in this study performed well for all three types of specimen (EDTA plasma, citrate plasma, and serum) with an interassay CV of less than 15%. Two additional quality control reagents, made locally from patient samples, were included in each assay to ensure quality performance during the entire study. An acceptable performance range for the quality control reagents was established prior to the start of the experiments.
Data Analysis
The samples collected from three study donors were assayed in duplicate, and the mean value from each donor was used for calculation. The data in the tables represent the mean and SD from the three study subjects. To illustrate the effect from different sample processing conditions, the data were normalized to corresponding controls shown in each of the tables. To analyze the complement biomarker data from patients with TTP, the data obtained were log-transformed to meet normal distribution for comparison. The data from each year were compared to each other and their differences determined using one-way analysis of variance (ANOVA) Duncan's multiple-range test with a significance of .05. All analysis was run by SPSS version 19 (SPSS, Chicago, IL).
Results
We first evaluated complement biomarker levels in different sample types. As shown in ❚Table 1❚, when samples were collected in EDTA-or citrate-anticoagulated tubes, plasma complement biomarker levels were very similar to each other. In contrast, the serum samples lacking citrate or EDTA obtained from the same group of study participants exhibited increased levels of complement biomarkers C4d and C3a. The mean values of C4d and C3a in serum were approximately two times higher than those in EDTA or citrate plasma, although statistical significance was not reached in this study involving limited sample sizes (n = 3). The levels of C5a, C5b-9, and factor Bb in serum, however, were similar to that in citrate or EDTA plasma.
Next, we examined how delaying sample processing affected the measurement of complement biomarkers. For both citrate and EDTA plasma, the results from different handling conditions were calculated as a ratio to the result obtained when the sample was processed freshly and immediately frozen at -80°C. Any results with a ratio greater than 1.5 were marked as meaningful (values in bold). As shown in ❚Table 2❚, complement proteins were relatively stable in citrated blood. Storage in a refrigerator or at RT for 3 to 4 hours prior to sample processing did not significantly affect the assay results. When the sample was stored for longer periods of time (>4 hours) at RT or (>24 hours) at 4°C, the levels of factor Bb, C5a, and C5b-9 biomarkers did not change significantly; however, levels of C4d and C3a were significantly increased. When blood was collected in EDTA tubes, the complement factors, including C4d and C3a, were generally more stable during storage. All five biomarkers were not significantly altered after storing at RT for up to 8 hours or when samples were stored in a refrigerator for 24 hours. Storage in a refrigerator for 48 hours prior to processing, however, was associated with increased C4d and C3a levels. a The values for mean and SD were calculated from three study donors. Reference ranges for each biomarker were established using commercially available citrate plasma samples from individual healthy donors (n = 40), purchased from George King.
❚Figure 1❚ shows the effects of different thawing conditions on the measurement of complement biomarkers. As shown in Figure 1A , most complement proteins were stable when the samples were thawed in an RT water bath for up to 60 minutes. The only exception was factor Bb in serum, which increased about twofold after thawing for 60 minutes. In contrast, all biomarkers except C4d were increased substantially and in a time-dependent manner when the serum or citrate sample was thawed at 37°C ( Figure 1B) . For example, after 1 hour of incubation, the amount of complement terminal pathway activator C5b-9 increased by 220-and 70-fold in serum and citrate plasma, respectively, whereas C4d levels were only slightly increased. In contrast to serum or citrate plasma samples, the complement factors in EDTA plasma were very stable. None of the biomarkers exhibited more than 1.5-fold changes over their baselines after a 1-hour incubation at 37°C. For all three types of specimen, thawing samples on ice for 3 hours led to no substantial changes in any of the five biomarkers (data not shown).
❚Table 3❚ shows the effect that different numbers of freeze/thaw cycles have on the complement biomarkers. For all three types of samples, there were no substantial changes in factor Bb, C3a, C5a, and C5b-9 levels over four freeze/ thaw cycles performed either on ice or at RT. C4d levels in all three sample types, however, showed a greater than 1.5-fold increase following one to two freeze/thaw cycles at RT. When the samples were thawed on ice, the C4d levels in serum and citrate plasma exhibited a greater than 1.5-fold increase after three freeze/thaw cycles.
In our TTP biorepository, pretreatment citrate plasma from each episode of TTP was collected, processed, and banked from each episode of TTP using a standard protocol. The number of TTP episodes encountered ranged from seven to 15 per year between 2006 and 2012. A total of 88 pretreatment samples were obtained from 51 patients with TTP during this period. We hypothesized that if long-term storage at -80°C were to affect complement biomarker levels, the levels would demonstrate a trend over time. The measurement of complement biomarker levels was performed in 2012 to evaluate if there were significant differences between the TTP samples collected in each of these 7 years. As shown in ❚Figure 2❚, the levels of the five complement biomarkers remained relatively similar. No significant difference was observed in the mean values of C4d, factor Bb, C3a, C5a, and C5b-9 over this time period, using a oneway ANOVA Duncan's multiple-range test.
Discussion
The study to define the sample requirements for a biomarker assay is a key analytical step prior to the process for clinical validation of a new biomarker. Deferring from an epidemiology study that defines the biological variations of a biomarker's performance in a population, the sample requirement analysis evaluates the effect of preanalytical factors that influence the test result. There is no scientific evidence that various sample handling conditions would affect individual people's samples in different ways. Thus, in a typical sample requirement study, the variables include sample collecting method (eg, EDTA plasma, citrate plasma, serum), sample storage condition, sample storage time, sample freeze/thaw cycles, and so on. In this study, each donor's sample was subjected to a total number of 62 various handling conditions for analysis. For each of the handling conditions, the assay was performed in duplicates, and the mean result from three study donors was shown. The data from this work therefore provide important guidelines for future studies regarding determination of the reference range for each of the complement biomarkers and evaluation of clinical utility of these biomarkers in disease diagnosis and prognosis.
In clinical laboratories, serum samples are routinely used for immunologic tests, including evaluation of the complement system. Citrated plasma samples are primarily used for study of the coagulation pathway. Many programs in the field of hemostasis have established biorepositories of plasma specimens collected longitudinally from patient cohorts. Given the recent discovery for the role of complement dysregulation in the development of TMAs, these banked citrate plasma samples are a valuable clinical resource for further defining the interaction between complement and coagulation systems. [11] [12] [13] 25, 26 Because of the ability of EDTA to inhibit complement activation in blood samples, some investigators have recommended using EDTA plasma for the study of complement activation. 27, 28 Thus, it is important to evaluate and compare how sample storage and processing affect the study results of the complement system in all three types of blood collection conditions. When blood samples are freshly processed for plasma, there are very small differences in the level of C4d, factor Bb, C3a, C5a, and C5b-9 between citrate and EDTA plasma samples. However, C4d and C3a levels in serum from the same individuals are markedly higher than that in the plasma samples. The data suggest that complement analysis should be performed using the same type of blood specimen from the study cohort for comparison.
For research studies, blood samples are often drawn from study patients and then stored for a period before laboratory staff is available to process and bank the sample. Therefore, it is important to assess how temporary storage after blood draw affects the study results. The data from this study suggest that complement factors are stable for a few hours prior to processing when blood is collected in either citrate or EDTA tubes and stored at RT or 4°C. However, when longer storage is anticipated prior to sample processing, EDTA blood is the preferred choice since it can keep complement factors largely stable for up to 8 hours at RT or 24 hours at 4°C.
In both clinical and research laboratories, samples are often collected, processed, and then frozen for later analysis. There is no standard procedure regarding how to thaw the specimen for complement study. Potentially, samples may be thawed on ice, at RT, or in a 37°C water bath. The length of thawing time is another factor likely affecting the study results. Our data suggest that when serum or citrate plasma is used for study, one should avoid using 37°C water baths to thaw the samples. Even with only a few minutes of incubation at 37°C, there are significant increases of complement activation in both serum and citrate plasma, particularly for the components in alternative (factor Bb) and common/ terminal pathways (C3a, C5a, C5b-9). In contrast, thawing in an RT water bath only minimally affects the test results as long as the samples are transferred in a timely manner on ice upon thawing. The complement factors in EDTA plasma are, however, relatively stable when samples are thawed at 37°C. In our study, the thawing conditions on ice were also evaluated and showed that the complement factors were not substantially affected when the samples were thawed and kept on ice for up to 3 hours.
The results from our study on the effect of freeze/thaw cycles suggest that complement factors in both alternative © American Society for Clinical Pathology and terminal pathways are stable after as many as four freeze/thaw cycles for all three types of specimen. The classic pathway component C4d is only marginally elevated upon the freeze/thaw process. Many biological samples are stored long term in biorepositories. There are questions regarding how stable complement factors are during the long-term storage at -80°C. Logistically, it is hard to set up an experiment to directly determine the effect of long-term storage on the integrity of the samples. Such study would involve the measurement of complement factors in the samples at the time of collection, store the samples for many years, and then measure the sample again using the same method with an identical analytical precision for comparison. To address this scientifically important issue in a feasible way, we examined the complement biomarker levels in the banked samples from our TTP cohort. It is known that patients with acquired TTP exhibit increased levels of complement activation at the time of an acute episode. 11, 12, 25 Our data show that there is no apparent trend of increases in complement biomarker levels over time in samples stored at -80°C. The overall mean and distribution of complement activation profiles do not vary significantly across the span of the past 6 years. The data strongly suggest that there is no significant complement activation in citrate plasma during long-term storage at -80°C. Although this study is not without limitations, it nevertheless clarifies, in the best way possible, an important issue regarding the impact of long-term sample storage on complement studies.
In summary, the analysis of complement biomarker levels is complex and subject to significant inaccuracies from sample collection and handling. Complement biomarker values in both research studies and the clinic should be interpreted carefully and in the context of all other available information. For both basic and clinical research, investigators must handle the study samples correctly to adequately evaluate activity of the complement system.
1. Same type of blood samples (EDTA plasma, citrate plasma, or serum) must be used in the same research and clinical study for comparison.
2. For citrate plasma samples, blood drawn from study participants should be processed within 4 hours if stored at RT and within 3 hours if refrigerated to prevent possible in vitro activation of the complement pathway.
3. For EDTA plasma samples, blood can be temporarily stored at RT for up to 8 hours or at 4°C for 24 hours prior to processing.
4. We strongly recommend thawing frozen samples either in an RT water bath or on ice. Frozen serum and citrate plasma samples should never be thawed at 37°C to avoid in vitro activation of complement factors.
5. Samples are acceptable for assays of complement biomarkers in alternative and common/terminal pathways for up to four freeze/thaw cycles using a proper procedure.
6. Complement factors appear stable in citrated plasma when stored up to 6 years at -80°C. ❚Figure 2❚ The effect of long-term storage at -80°C on the measurement of complement biomarkers. The data of complement biomarkers from each year were log-transformed to meet normal distribution. The mean ± SD values are plotted for comparison.
